M&A, Pharma

Forest Laboratories and Aptalis enters into m&a deal

Posted on 09 January 2014

Tags: , ,

Forest Laboratories has entered into a definitive m&a deal to acquire Aptalis for $2.9 billion in cash from its shareholders.

The m&a deal, which requires review by anti-trust authorities in the US and Canada, is expected to be accretive to Forest’s FY2015 non-GAAP EPS.

Forest intends to acquire Aptalis from its shareholders for $2.9 billion in cash.

Forest expects to use a combination of cash on hand and debt to fund the transaction.

Forest has secured commitment for a $1.9 billion bridge facility.

View the full article at Reuters

For further deal information visit Current Agreements (subscription required)

 

Related

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply